ORMP: Oramed Pharmaceuticals Inc. Stock

by  •  • Comments Off on ORMP: Oramed Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 94.41
Enterprise Value ($M) 135.44
Book Value ($M) 162.89
Book Value / Share 4.02
Price / Book 0.58
NCAV ($M) 104.93
NCAV / Share 2.59
Price / NCAV 0.90

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.04

Liquidity (mrq)
Quick Ratio 3.06
Current Ratio 3.06

Balance Sheet (mrq) ($M)
Current Assets 162.58
Assets 220.55
Liabilities 57.66
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.34
Operating Income -15.77
Net Income 5.53
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -10.29
Cash from Investing -73.04
Cash from Financing 51.98

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-22 13D Kidron Nadav 5.70 74.47

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 54,096 233,840 23.13
2024-04-17 29,980 142,735 21.00
2024-04-16 24,641 31,194 78.99
2024-04-15 10,009 77,360 12.94

(click for more detail)

Similar Companies
ONVO – Organovo Holdings, Inc. ORGO – Organogenesis Holdings Inc.
ORGS – Orgenesis Inc. OTLK – Outlook Therapeutics, Inc.
PALI – Palisade Bio, Inc.


Financial data and stock pages provided by
Fintel.io